---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-24-000026"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T14:09:05.853879+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q2 revenue up 12% to $3.55B, EPS beats; EU approves Dupixent for COPD

## Summary
- Total revenue $3.55B (+12% YoY); GAAP diluted EPS $12.41 (+46%); non-GAAP diluted EPS $11.56 (+13%).
- Dupixent global net sales up 27% to $3.56B; EU approved for COPD; FDA decision expected Sept 27, 2024.
- EYLEA HD/EYLEA U.S. sales $1.53B (+2%), including $304M from EYLEA HD.
- Libtayo global net sales up 42% to $297M; pipeline progress in obesity, gene therapy, oncology.
- New $3B share repurchase authorization; $601M repurchased in Q2; 2024 guidance updated.

## SEC filing metadata
- accession: 0001804220-24-000026
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422024000026/0001804220-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422024000026/regn-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-24-000026
- JSON: https://secwatch.observer/filing/0001804220-24-000026.json
- Plain text: https://secwatch.observer/filing/0001804220-24-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.